Rothschild & Co Downgrades Moderna to Sell, Raises Price Target to $81

Benzinga Newsdesk www.benzinga.com Negative 48.4%

Neg 48.4% Neu 0% Pos 0%

Rothschild & Co analyst Simon Baker downgrades Moderna (NASDAQ:MRNA) from Neutral to Sell and raises the price target from $40 to $81.